Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra

Osteoporosis International

Volumn 20, Issue 4, 2009, Pages 647-652

  Diab, T ^a,c   Allen, M R ^a   Burr, D B ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Animal models; Anti remodeling; Bisphosphonates; Histomorphometry

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANIMAL EXPERIMENT; ARTICLE; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; FEMALE; FEMUR NECK; MORPHOMETRICS; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VERTEBRA; ANIMAL; ANIMAL MODEL; DOG; DOSE RESPONSE; DRUG EFFECTS; LUMBAR VERTEBRA; PHYSIOLOGY;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMUR NECK; LUMBAR VERTEBRAE; MODELS, ANIMAL;

EID: 62149101092     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0717-9     Document Type: Article

References (34)

1. AM Parfitt CH Mathews AR Villanueva 1983 Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss J Clin Invest 72 1396 1409
2. SC Manolagas RL Jilka 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis N Engl J Med 332 305 311
3. PJ Meunier C Roux E Seeman 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 68
4. M Gass B Dawson-Hughes 2006 Preventing osteoporosis-related fractures: an overview Am J Med 119 4 Suppl 1 S3 S11
5. K Henriksen LB Tanko P Qvist 2007 Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases Osteoporos Int 18 681 685
6. DM Black SR Cummings DB Karpf 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541
7. SR Cummings DM Black DE Thompson 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082
8. SL Greenspan ST Harris H Bone 2000 Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis Am Fam Physician 61 2731 2736
9. HG Bone D Hosking JP Devogelaer 2004 Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 12 1189 1199
10. SE Papapoulos SA Quandt UA Liberman 2005 Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Osteoporos Int 16 468 474
11. CJ Rosen MC Hochberg SL Bonnick 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 51
12. P Garnero E Hausherr MC Chapuy 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study J Bone Miner Res 11 1531 1538
13. LJ Melton 3rd S Khosla EJ Atkinson 1997 Relationship of bone turnover to bone density and fractures J Bone Miner Res 12 1083 1091
14. S Sarkar JY Reginster GG Crans 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J Bone Miner Res 19 394 401
15. DC Bauer DM Black P Garnero 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J Bone Miner Res 19 1250 1258
16. BL Riggs LJ Melton 3rd WM O'Fallon 1996 Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy Bone 18 3 Suppl 197S 201S
17. BL Riggs LJ Melton 3rd 2002 Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density J Bone Miner Res 17 11 14
18. MP Akhter JM Lappe KM Davies 2007 Transmenopausal changes in the trabecular bone structure Bone 41 111 116
19. P Chavassieux E Seeman PD Delmas 2007 Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease Endocr Rev 28 151 164
20. B Borah TE Dufresne EL Ritman 2006 Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography Bone 39 345 352
21. MR Forwood DB Burr Y Takano 1995 Risedronate treatment does not increase microdamage in the canine femoral neck Bone 16 643 650
22. T Mashiba S Hui CH Turner 2005 Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs Calcif Tissue Int 77 180 185
23. MR Allen DB Burr 2007 Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment J Bone Miner Res 22 1759 1765
24. MR Allen K Iwata R Phipps 2006 Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate Bone 39 872 879
25. J Foldes MS Shih AM Parfitt 1990 Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces J Bone Miner Res 5 1063 1067
26. AM Parfitt MK Drezner FH Glorieux 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J Bone Miner Res 2 595 610
27. E Seeman 2007 Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41 308 317
28. S Gonnelli C Cepollaro C Pondrelli 1999 Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis Calcif Tissue Int 65 359 364
29. JR Tucci RP Tonino RD Emkey 1996 Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis Am J Med 101 488 501
30. CV Odvina JE Zerwekh DS Rao 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301
31. PM Chavassieux ME Arlot C Reda 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis J Clin Invest 100 1475 1480
32. RR Recker RS Weinstein CH Chesnut 3rd 2004 Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study Osteoporos Int 15 231 237
33. EF Eriksen F Melsen E Sod 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis Bone 31 620 625
34. RR Recker PD Delmas J Halse 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J Bone Miner Res 23 6 16